Proven Impact of an Advanced Air Purification System in the Reduction of Infectious Airborne and Surface Pathogens, Concomitant Reduction of Hospital-acquired Infections and Length of Stay, and Improvement in Health-care Economics
A peer-reviewed, IRB-approved operational clinical study examining the impact of LifeAire’s advanced air purification technology on airborne and surface pathogen burden, hospital-acquired infection rates, patient length of stay, and healthcare economics. Conducted at St. Luke’s University Health Network, the study compared a LifeAire-protected unit with a HEPA-only control unit over 12 months across 8,255 patients. Documented outcomes in the protected unit included a 99.99% reduction in viable airborne pathogens, a 97% reduction in surface pathogens, a 30% reduction in hospital-acquired infections, a 39% reduction in patient length of stay, and a 23% improvement in per-bed economics. Published in the Journal of Global Infectious Diseases, March 2023.